The post Altcoin interest falls: Could an Ethereum breakout spark altseason? appeared on BitcoinEthereumNews.com. The market has brought risk management back toThe post Altcoin interest falls: Could an Ethereum breakout spark altseason? appeared on BitcoinEthereumNews.com. The market has brought risk management back to

Altcoin interest falls: Could an Ethereum breakout spark altseason?

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The market has brought risk management back to the forefront.

From a technical standpoint, capital inflows over the past week have pushed high‑cap assets above their month‑to‑month highs, reigniting the risk‑on sentiment that faded after last year’s Q4 crash.

Yet, the next move remains uncertain. Bitcoin [BTC] is chopping around $70k, while Ethereum [ETH] hovers near $2k, both creating indecision in directional bias and setting up a potential trap for both bulls and bears.

Source: TradingView (ETH/USDT)

Historically, such indecision has moved capital toward alternative assets. 

However, with no altcoin rally materializing, the market is instead capitalizing on bearish sentiment. Arkham Intelligence identified a whale who has already secured $4.5 million in profits by shorting altcoins.

Meanwhile, Social Volume around altcoins has fallen sharply, dropping from 750 in July 2025 to just 33, according to Santiment. This decline in market interest further reinforces bearish positioning, creating an optimal setup for bears to capitalize on altcoin trends.

That said, BTC is testing resistance, signaling that risk management is critical. In this context, is this bearish positioning truly low-risk, or could an Ethereum breakout flip the market back in favor of bulls?

Ethereum breakout could unlock rotation across altcoins

Ethereum’s bullish metrics are timing-sensitive.

On the technical front, the ETH/BTC ratio continues to consolidate below 0.03. This consolidation follows a first higher high since the mid-January 0.035 peak, signaling that Ethereum is slowly regaining competitive flows.

Notably, this technical setup is further reinforced by stablecoin supply, as Artemis data shows over $500 million in stablecoin liquidity absorbed on Ethereum in the past 24 hours, outperforming every other chain.

Source: Artemis Terminal

Consequently, this influx is driving capital flows into key growth sectors, with Ethereum dominating the tokenized sector at nearly 60% market share and recording a 0.43% increase in daily Total Value Locked.

In essence, strong on-chain liquidity, targeted capital rotation, and strategic accumulation are driving the current ETH/BTC consolidation, signaling that investors are positioning bullishly around Ethereum on both technical and fundamental grounds.

As the largest altcoin, a breakout in ETH would naturally redirect capital across altcoins, and with risk management back in focus, this setup creates conditions ripe for a massive short squeeze and subsequent altcoin rally.


Final Summary

  • With no altcoin rally, whales are profiting from bearish positions. In turn, this is creating an optimal setup for bears to capitalize on altcoin weakness.
  • rong on-chain metrics suggest an Ethereum breakout could redirect capital across altcoins and trigger a massive short squeeze.
Next: BNB Chain outpaces rivals in stablecoin activity – Why is capital moving here?

Source: https://ambcrypto.com/altcoin-interest-falls-could-an-ethereum-breakout-spark-altseason/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09